CT-Guided Interstitial HDR-Brachytherapy for Recurrent Glioblastoma Multiforme: A 20-Year Single-Institute Experience
PURPOSE: To report our results of computed tomography-guided interstitial high-dose-rate (HDR) brachytherapy (BRT) in the treatment of patients with recurrent inoperable glioblastoma multiforme (GBM). PATIENTS AND METHODS: Between 1995 and 2014, 135 patients were treated with interstitial HDR BRT for inoperable recurrent GBM located within previously irradiated volumes. Patient's median age was 57.1 years (14-82 years). All patients were pretreated with surgery, postoperative external beam radiation therapy (EBRT) and systemic chemotherapy (ChT). The median recurrent tumor volume was 42cm(3) (2-207cm(3)). The prescribed HDR dose was median 40Gy (30-50Gy) delivered in twice-daily fractions of 5.0Gy over consecutive days. No repeat surgery or ChT was administered in conjunction with BRT. Survival from BRT, progression-free survival (PFS), toxicity as well as the impact of several prognostic factors were evaluated. RESULTS: At a median follow-up of 9.2 months, the median overall survival following BRT and the median PFS were 9.2 and 4.6 months, respectively. Of the prognostic variables evaluated in univariate analysis, extent of surgery at initial diagnosis, tumor volume at recurrence, as well as time from EBRT to BRT reached statistical significance, retained also in multivariate analysis. Eight patients (5.9%) developed treatment-associated complications including intracerebral bleeding in 4 patients (2.9%), symptomatic focal radionecrosis in 3 patients (2.2%), and severe convulsion in 1 patient (0.7%). CONCLUSIONS: For patients with recurrent GBM, interstitial HDR BRT is an effective re-irradiation method for even larger tumors providing palliation without excessive toxicity.
Chatzikonstantinou, G., Zamboglou, N., Archavlis, E., Strouthos, I., Zoga, E., Milickovic, N., Hilaris, B., Baltas, D., Rodel, C., & Tselis, N. (2018). CT-Guided Interstitial HDR-Brachytherapy for Recurrent Glioblastoma Multiforme: A 20-Year Single-Institute Experience. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ...[et al], 194 (12), 1171-1179. https://doi.org/10.1007/s00066-018-1358-3